2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, CHIP, Genomics, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, T Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

790 A multicenter Phase II study of combination mogamulizumab and extracorporeal photopheresis (ECP) in erythrodermic CTCL

Christiane Simone Querfeld, MD, PhD, Lu Chen, PhD2, Pamela Allen, MD3, Laura Catherine Schultz, MD4, Alyssa Wu, BS5, Jeralyn Quach, CRN6, Allison C Rosenthal, DO7, Jasmine Zain, M.D.8, Diane Lynne Smith, PhD9, Courtney Johnson, MD, PhD10, Christina Poh, MD11, Steven T Rosen, MD12, Aaron Mangold, MD13
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 Emory Winship Cancer Institute, Atlanta, Georgia, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 Mayo Clinic Arizona, Scottsdale, Arizona, United States

Background: Mogamulizumab (Moga) is a potent anti-CCR4 monoclonal antibody with marked antitumor efficacy in cutaneous T-cell lymphoma (CTCL). However, systemic CCR4 targeting simultaneously depletes effector T-regulatory cells (eTregs; CD45RA⁻Foxp3⁺⁺CCR4⁺), which possess potent immunosuppressive activity. This depletion can disrupt immune equilibrium, triggering autoimmunity and immune-related adverse events (irAEs) such as Moga-Associated Rash (MAR). We hypothesized that combining mogamulizumab with Extracorporeal Photopheresis (ECP) provides complementary immune responses with non-overlapping toxicities. Specifically, ECP is anticipated to restore immune balance by promoting regulatory T cells, inducing apoptosis in overactive lymphocytes, and modulating antigen-presenting cells without causing generalized immunosuppression and attenuating MAR and other autoimmune irAEs, resulting in a safer, more durable, and synergistic therapeutic response.

Methods: Patients received Moga weekly 1.0 mg/kg for 4 weeks followed by a 1.0 mg/kg Q2W dosing in subsequent cycles, alternating with ECP given on two consecutive days every other week starting in Cycle 2 for up to 12 cycles (NCT04930653). The primary objective was to assess tolerability and overall response rate (ORR), secondary endpoints included complete response (CR) rate, time to response, progression-free survival, overall survival and toxicities. Exploratory endpoints were to explore the tumorigenic and immunogenic response of combination therapy.

Results: As of August 3, 2026, the study has enrolled 25 pts with a median age of 63.8 years and male predominance (19/6) and an equal distribution of erythrodermic mycosis fungoides (52%) and Sézary Syndrome (48%). At baseline one pt (4%) presented at stage IB (T2 with circulating cells), 48% were stages IIIA/IIIB, and 48% were stages IVA1/A2. The median follow-up was 21.1 months. Three patients were not evaluable for response because they did not receive ECP: 2 discontinued after Cycle 1 due to disease progression and consent withdrawal, respectively, and one lacked peripheral vein access and could not have line placement for ECP. Five additional patients are pending response assessment. Among the 17 response-evaluable patients, the best global ORR was 65% (12/17), including a 6% CR rate (1/17), a 59% PR rate (11/17), and 5 patients with SD (29%) with a median onset to best global response of 2.8 months (range: 0.9–11.5 months). Skin-specific responses yielded 5 CR, 9 PR, and 3 SD. MAR occurred in 8/17 (47%) of patients with a median onset of 5.6 months (range: 0.5–10.6 months) and mostly occurred after starting ECP and during cycle 5 of the combination regimen and occurred in a single patient during cycle 1 receiving weekly Moga dosing. The majority of MAR cases were minimal and low-grade: Grade 1 in 5 patients (29%), Grade 2 in 2 patients (11%), and Grade 3 in 1 patient (6%). Management of MAR included topical steroids alone in 4 patients systemic steroids, JAK inhibitor (ruxolitinib), JAK inhibitor combined with systemic steroids and oral weekly methotrexate combined with systemic steroid in one patient each.

Conclusion: The combination yielded a high global ORR of 65% and remarkable skin clearance (5 CRs) in advanced CTCL, with a rapid median response onset. The preliminary safety evaluation showed a predictable and manageable profile. While MAR was a common immune-related adverse event, it was characterized by a very mild onset, presenting predominantly as Grade 1 toxicity indicating that ECP mitigates severity.

Christiane Simone Querfeld, MD, PhD: SLAMBio Therapeutics - Honoraria; Citius Pharmaceuticals - Honoraria; Helsinn - Honoraria; Kyowa Kirin - Honoraria; Kyowa Kirin - Research Funding; SLAMBio Therapeutics - Consultancy (Includes expert testimony); Helsinn - Membership on a Board/Advisory Committee; Kyowa Kirin - Membership on a Board/Advisory Committee; Citius Pharmaceuticals - Membership on a Board/Advisory Committee; SLAMBio Therapeutics - Membership on a Board/Advisory Committee